abstract: INTRODUCTION AND OBJECTIVES: The concentration of certain proinflammatory cytokines has been found to be elevated in @entity1 with @entity1187 . Many studies have shown that coronary ischemic accidents do not show a uniform distribution throughout the day, but instead exhibit rhythmic variations. The objective of this study is to determine whether there is a circadian pattern of variation in the concentrations of proinflammatory cytokines in @entity1 with @entity583 . @entity1 AND METHOD: The sample included 40 @entity1 with @entity583 and 40 controls. Levels of @entity38453 were determined in the first 24 hours after the acute coronary ischemic episode. Blood samples were extracted at 3:00 a.m. (period of darkness) and at 10:00 a.m. (period of daylight). RESULTS: Both groups were similar in age, sex distribution, and coronary risk factors. @entity650 levels showed a significant variation between daylight and nighttime concentrations in @entity1 with @entity583 and controls (41.93 5.90/100.39 13.60 vs 25.76 4.45/52.67 7.73 pg/ml). However, @entity650 concentrations were higher in the @entity583 group than in the control group. @entity1356 concentrations did not vary between daylight and darkness. CONCLUSIONS: In both the control group and @entity583 group, @entity650 concentrations varied between daylight and darkness. @entity1 with @entity583 shown a higher concentration of @entity650 secondary to the physiological response to tissue damage. Circadian variations can affect the measurements obtained for different physiological and biochemical parameters.

title: [Circadian variations in proinflammatory cytokine concentrations in XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndrome']

entities_list: @entity650 :: ('3569', 'Gene') :: ['Interleukin 6', 'interleukin 6']

entities_list: @entity1356 :: ('3553', 'Gene') :: ['Interleukin 1 beta']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['acute myocardial infarction']

answer: @entity583 :: (MESH:D009203,Disease) :: ['acute myocardial infarction']


abstract: A new aqueous nanoparticle system has been developed using complex coacervation employing the oppositely charged polymers @entity12279 ( @entity8681 ) and dextran sulfate (DS), with @entity17562 as a stabilizing agent. @entity2379 ( @entity11015 ) was loaded into the nanoparticles as a model drug. The nanoparticles contained @entity8681 and DS in the weight ratio of approximately 1:2. They possessed a zeta potential of approximately +30 mV and demonstrated a narrow size distribution in the range 100-600 nm with a polydispersity index of 0.2. Electron microscopy revealed spherical nanocapsules with a smooth surface. Very favorable drug entrapment and recovery efficiencies of up to 85% were routinely observed. Processing parameters, such as the pH of the @entity8681 solutions, ratio of the two polymers, as well as the concentrations of DS and @entity17562 , all played a significant role in controlling particle size. Dissolution studies demonstrated a fast release that is dependent on the model drug solubility. The @entity11015 -loaded nanoparticles displayed no @entity137 in tissue culture in contrast to free drug and were almost as efficacious as free drug in killing @entity5132 . Advantages of this simple technique are (1) ease of manufacturing and mild preparation conditions, (2) employment of completely aqueous processing conditions, (3) use of biocompatible polymers that can be prepared aseptically, (4) ability to control their size, and (5) a high level of drug entrapment.

title: Formulation and characterization of @entity2379 - XXXX -dextran sulfate nanoparticles.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity2379 :: ('MESH:D000666', 'Chemical') :: ['Amphotericin B']

entities_list: @entity12279 :: ('MESH:D011094', 'Chemical') :: ['polyethylenimine']

entities_list: @entity5132 :: ('5476', 'Species') :: ['Candida albicans']

entities_list: @entity17562 :: ('MESH:D019287', 'Chemical') :: ['zinc sulfate']

answer: @entity12279 :: (MESH:D011094,Chemical) :: ['polyethylenimine']


abstract: Intramuscular injection of the naturally occurring @entity3774 (PGF2alpha) to sexually mature female @entity1707 induces luteolysis and rapidly elicits a behavioural response consistent with pre-partum nest-building. Intramuscular injection of the synthetic @entity3774 ( @entity2669 ) also induces luteolysis but no nest-building behaviour is observed. The effects of PGF2alpha, but not @entity2669 , on nest-building behaviour may be mediated via peripheral PGF2alpha receptors (FP) or via direct action on central FP receptors. We have previously shown FP receptor mRNA to be localized in porcine paraventricular nucleus (PVN), supraoptic nucleus (SON) and pars dorso-medialis of the suproptic nucleus (SOD), suprachiasmatic nucleus, choroid plexus and anterior and intermediate pituitary lobes. In this experiment, we examined hypothalamic expression of the immediate early genes @entity51876 and @entity26105 mRNA after treatment with @entity3774 or @entity2669 . Twenty-one 8-month-old nulliparous female @entity1707 (gilts) were injected intramuscularly with a luteolytic dose of PGF2alpha (15 mg), @entity2669 (175 microg) or saline control, their behaviour was recorded and they were killed 60 min later. Coronal hypothalamic sections and control ovarian tissues were incubated with 45-mer oligonucleotide probes complementary to porcine @entity51876 and @entity26105 genes using standard in situ hybridization histochemistry techniques. Significantly higher @entity51876 and @entity26105 mRNA expression was found in PGF2alpha-treated compared to saline or @entity2669 -treated @entity1707 in the PVN, SON and SOD. Significantly higher @entity51876 and @entity26105 mRNA expression was found in corpus lutea of PGF2alphaand @entity2669 -treated @entity1707 compared to saline controls. Treatment with PGF2alpha induced nest-building behaviour whereas treatment with @entity2669 and saline did not. This suggests that PGF2alpha, or one of its metabolites, and not @entity2669 , crosses the blood-brain barrier and acts directly on hypothalamic receptors to mediate its effect on nest-building behaviour.

title: @entity3774 -induced nest-building behaviour is associated with increased hypothalamic @entity51876 and XXXX mRNA expression.

entities_list: @entity2669 :: ('MESH:D003008', 'Chemical') :: ['cloprostenol']

entities_list: @entity3774 :: ('MESH:D015237', 'Chemical') :: ['PGF2alpha', 'prostaglandin F2alpha']

answer: @entity26105 :: (396913(Tax:9823),Gene) :: ['c-jun']


abstract: PURPOSE: To determine the proportion of solid organ transplant recipients developing periocular @entity1489 and to describe the morbidity of these @entity5 in transplant recipients. DESIGN: Cohort study. @entity1 : Consecutive @entity1 undergoing solid organ transplantation at the Cleveland Clinic between 1990 and  2008. METHODS: The charts of all @entity1 receiving a solid organ transplant from 1990-2008 evaluated in the dermatology department for a subsequent biopsy-proven head and neck malignancy through April 2015 were reviewed. @entity1 with a periocular region @entity1489 ( @entity1489 ) or a nonperiocular @entity1489 causing a complication requiring eyelid surgery were included. Charts were reviewed for demographic data; transplant date, type, and source; immunosuppressive agents received at diagnosis; and type of @entity1489 , number of nonperiocular NMSCs, ophthalmologic findings, and periocular sequelae after the repair. MAIN OUTCOME MEASURES: Primary outcome measures included the type, location, final defect size, @entity5 -node-metastasis classification, presence of perineural invasion, and reconstruction technique(s) used for each periocular @entity1489 . Secondary outcome measures included the type and treatment of ocular sequelae due to nonperiocular facial @entity1489 . RESULTS: A total of 3489 @entity1 underwent solid organ transplantation between 1990 and 2008. Of these, 420 @entity1 were evaluated in the dermatology clinic for biopsy-proven @entity1489 of the head and neck during the study period, and 11 @entity1 (15 @entity5 ) met inclusion criteria. Nine @entity1 developed 12 periocular @entity5 and 3 @entity1 required eyelid surgery for facial @entity5 outside the periocular zone. All 11 @entity1 developed a @entity957 (14 @entity5 ), and 1 @entity1 (1 malignancy) also developed a @entity1491 . There was orbital invasion in 4 cases and paranasal and/or cavernous sinus invasion in 3 cases. Two @entity1 underwent exenteration. Seven cases required reconstruction with a free flap or graft. Periocular sequelae included @entity4549 (6 @entity5 ), @entity936 and/or exposure symptoms (8 @entity5 ), @entity1018 (3 @entity5 ), and @entity2103 (5 @entity5 ). CONCLUSIONS: @entity957 affecting the periocular region represents a risk of solid organ transplantation and may produce significant ocular morbidity, including the need for major eyelid reconstruction, globe loss, and disfiguring surgery.

title: Periocular XXXX in Solid Organ Transplant Recipients.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PARTICIPANTS']

entities_list: @entity1018 :: ('MESH:D054062', 'Disease') :: ['unilateral vision loss']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'malignancies']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['nonmelanoma skin cancer', 'NMSC']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma', 'Squamous cell carcinoma']

entities_list: @entity2103 :: ('MESH:D005155', 'Disease') :: ['facial nerve paresis']

entities_list: @entity4549 :: ('MESH:D004483', 'Disease') :: ['lower eyelid ectropion']

entities_list: @entity1491 :: ('MESH:D002280', 'Disease') :: ['periocular basal cell carcinoma']

answer: @entity1489 :: (MESH:D012878,Disease) :: ['Skin Cancer']


abstract: AIMS: To assess the efficacy and safety of neoadjuvant chemotherapy (NAC) for advanced @entity356 (AGC). METHODS: By searching electronic databases (PubMed, Embase, Cochrane Library) and ASCO proceedings from 1990 to 2012, all randomized controlled trials (RCTs) which compared the effect of NAC-combined surgery versus surgery alone in AGC were included. All calculations and statistical tests were performed using RevMan 5.0 software. RESULTS: 12 RCTs with a total of 1820 @entity1 were included. All @entity1 had locally advanced but resectable @entity356 and received NAC. NAC can slightly improve the survival rate (OR = 1.32, 95% confidence interval (CI): 1.07-1.64, P = 0.01), with little or no significant benefits in subgroup analyses between either different population or regimens. NAC can significantly improve the 3-year progression-free survival (PFS) (OR: 1.85, 95% CI: 1.39-2.46, p < 0.0001), @entity5 down-staging rate (OR: 1.71, 95% CI: 1.26, 2.33, p = 0.0006) and R0 resection rate (OR: 1.38, 95% CI: 1.08-1.78, P = 0.01) of @entity1 with AGC. There was no difference between the two arms, in terms of relapse rates (OR: 1.03, 95% CI: 0.60-1.78, p = 0.92), operative complications (OR: 1.20, 95% CI: 0.90-1.58, p = 0.21), perioperative mortality (OR: 1.14, 95% CI: 0.64-2.05, p = 0.65) and grade 3/4 adverse effects: gastrointestinal problem (OR: 0.57, 95% CI: 0.25-1.30, p = 0.18), @entity1431 (OR: 0.88, 95% CI: 0.41-1.91, p = 0.75), @entity882 (OR: 1.27, 95% CI: 0.27-5.93, p = 0.76). CONCLUSION: NAC is effective and safe. However, further prospective multi-national and multi-center RCTs are still needed in order to investigate the long-term oncological and functional outcomes to define the clinical benefits of NAC and the most effective strategies for AGC.

title: Clinical effectiveness of neoadjuvant chemotherapy in advanced XXXX : an updated meta-analysis of randomized controlled trials.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']


abstract: BACKGROUND: The ability to understand factors associated with an increased duration of missed work postoperatively could be used to more effectively select @entity1 with the greatest opportunity for a successful outcome. We set out to determine the effect of preoperative @entity308 on postoperative return to work in @entity1 undergoing @entity2649 ( @entity2649 ) for degenerative spondylolisthesis. METHODS: Fifty-eight @entity1 undergoing @entity2649 for symptomatic grade I @entity179 were included in this analysis. @entity1 demographics, clinical presentation, indications for surgery, radiologic studies, and operative variables were assessed for each case. @entity1 -assessed outcome measures were obtained prospectively at baseline and 2 years postoperatively. To understand the factors associated with prolonged return to work, univariate linear regression analysis and stepwise multivariate Cox proportional hazards model was used. RESULTS: All @entity1 -reported outcomes assessed were significantly improved 2 years after @entity2649 (P < 0.001). Of the 32 @entity1 working preoperatively, 26 (81%) returned to work postoperatively. Median time to return to work was 56 days (range, 10-150 days). Independent of @entity1 age; preoperative @entity158 , disability, and quality of life; and extent of postoperative improvement, increased preoperative Zung @entity308 score remained associated with prolonged return to work (P  = 0.02). CONCLUSIONS: Independent of postoperative improvement in @entity158 , disability, and quality of life, the extent of preoperative @entity308 was an independent predictor of time to return to work in @entity1 undergoing @entity2649 for spondylolisthesis, suggesting that regardless of how successful @entity2649 surgery may be at improving a @entity1 's @entity158 , disability, or quality of life, greater @entity308 will delay or prohibit their ability to return to work postoperatively.

title: Extent of XXXX Is Associated with Return to Work After Lumbar Fusion for Spondylolisthesis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity2649 :: ('MESH:C563613', 'Disease') :: ['TLIF', 'transforaminal lumbar interbody fusion']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['degenerative lumbar spondylolisthesis']

answer: @entity308 :: (MESH:D003866,Disease) :: ['Preoperative Depression']


abstract: OBJECTIVE: To estimate the frequency of subtelomeric rearrangements in @entity1 with sporadic and @entity1032 (IMR). METHODS: A total of 18 IMR @entity1 were taken for the study. Selection criteria included no known syndromes or @entity2008 and known causes of IMR. All @entity1 signed an informed consent to participate. Chromosome analysis was carried out on all @entity1 to rule out gross chromosome abnormalities. Lymphocyte cultures were initiated and harvested using standard protocols. For fluorescence in situ hybridization (FISH), Chromoprobe Multiprobe-T system was used. This system consists of 24 embossed areas with each area having one reversibly bound subtelomere probe for a specific chromosome. The subtelomere probes were differentially labeled with green fluorescence for short arm and orange for the long arm. Hybridization, washing and staining are done using standard protocols. A minimum of 5 metaphases were analyzed per chromosome per @entity1 . RESULTS: A total of 2 subtelomeric rearrangements were detected (11.1%). Case 1 involved a 17-year-old with severe @entity90 , profound @entity2319 and @entity154 with reciprocal translocation t(3;7)(q26.2; p15.1). The second case involved a 4.6-year-old with mild @entity245 and a terminal deletion of the long arm of chromosome 2, del(2) (q37.3). The frequency of abnormalities detected in our study is in agreement with published reports. CONCLUSION: Subtelomeric screening with FISH is a useful tool for investigation of IMR, however, it is not cost effective in all cases. Conventional chromosome analysis coupled with targeted FISH testing might be the optimal strategy for investigation of IMR.

title: Subtelomeric rearrangements in idiopathic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['dysmorphic features']

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['non-syndromic idiopathic mental retardation']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['developmental delay']

entities_list: @entity2008 :: ('MESH:D002869', 'Disease') :: ['chromosomes abnormalities']

answer: @entity1032 :: (MESH:D008607,Disease) :: ['mental retardation']


abstract: OBJECTIVE: Study of @entity412 distribution and their association with other major @entity65 risk factors in 11 provinces. METHODS: Twenty-seven thousand and sixteen @entity1 in 11 provinces, aged 35 - 64, were screened for @entity65 risk factors. RESULTS: (1) Results of plasma @entity412 level distribution showed that there was significant difference among 11 province, the highest/lowest ratio was 2.3. (2) Plasma @entity412 level was higher in @entity1 than in @entity1 (P < 0.001). (3) The prevelance of @entity2298 was the most frequent @entity164 . (4) Multiple stepwise regression analysis showed that total @entity165 , high-density lipoprotein @entity165 , body mass index, blood pressure, blood @entity413 and physical activity, significantly and independently correlated with @entity2298 prevelance. (5) There existed aggregation of risk factors in @entity2298 . Seventy-one point zero percent of @entity2298 had at least one other risk factors in @entity1 and 74.4% in @entity1 , while it was 53.8% @entity1 and 52.2% @entity1 of those with non @entity2298 (P < 0.01). CONCLUSION: Our date indicated that fasting @entity1674 were associated with more @entity4288 factors and could serve as a marker for several @entity65 risk factors. More @entity1 with @entity2298 combined with other situation of @entity209 thus might have higher risks.

title: [Study of XXXX distribution aged 35 - 64, and their association with other @entity65 risk factors in 11 provinces].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'persons', 'men']

entities_list: @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia']

entities_list: @entity4288 :: ('MESH:D001161', 'Disease') :: ['arteriosclerosis']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndromes']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity164 :: ('MESH:D017827', 'Disease') :: ['type of the dislipidemia']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity412 :: (CHEBI:17855,Chemical) :: ['triglyceride']


abstract: All @entity1 over the age of 60 who experienced @entity410 between 1979-83, were registered. The number of @entity204 was registered until July 2, 1985. Included were 162 @entity1 who received no anti- @entity302 drugs prior to the study period; 87 @entity1 had established @entity302 at the time of admission. The number of @entity204 among previously untreated @entity1 significantly exceeded expectation. Mortality was not significantly correlated to severity of @entity302 . In @entity1 with @entity1313 all but one died within the first year. Mortality among @entity1 with postapoplectic @entity410 was significantly higher than expected being especially during the first year. Numbers of @entity204 among @entity1 with @entity410 of unknown cause did not differ from the expected, neither did causes of @entity204 . Numbers of @entity204 in @entity1 with established @entity302 at the time of admission was significantly higher than expected although none had @entity5 and only 4 had postapoplectic @entity410 thus illustrating the influence of selecting @entity1 with @entity302 . Eleven @entity1 died suddenly and unexpectedly of unknown cause, which was more than expected. These @entity1 were found dead under circumstances compatible with @entity204 occurring during @entity410 . @entity302 was mentioned on the @entity204 certificate in only one case, indicating that the frequency of sudden, unexpected @entity204 among @entity302 could easily be underestimated.

title: @entity302 in the elderly: life expectancy and causes of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant tumours']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['chronic active epilepsy', 'epileptic', 'epilepsy', 'epileptics', 'Epilepsy']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']

answer: @entity204 :: (MESH:D003643,Disease) :: ['death']


abstract: UNASSIGNED: Autophagy has dual functions in cell survival and death. However, the effects of autophagy on @entity5 cell survival or death remain controversial. In this study, we show that Autophagy can mediate @entity204 ( @entity204 ) of @entity5 cells in responding to @entity5303 ( @entity5303 )-induced @entity519 in a @entity8783 -independent but @entity10614 ( @entity10614 )-dependent manner. Although @entity10614 is not directly induced by @entity5303 , its constitutive expression is essential for @entity5303 -induced @entity204 . The @entity10614 -mediated autophagic @entity204 requires interplays with endoplasmic reticulum (ER) and/or mitochondria. In this process, @entity10614 plays a central role in regulating ER stress protein CCAAT/enhancer-binding protein (C/EBP) homologous protein ( @entity3726 ) and mitochondrial protein second mitochondria derived activator of caspases ( @entity17205 ). Two pathways for autophagic @entity204 in @entity5 cells responding to @entity519 have been identified: @entity10614 / @entity3726 / @entity17205 pathway and @entity10614 / @entity17205 pathway, which are probably dependent on the context of cell lines. The former is more potent than the latter for the induction of @entity204 at the early stage of @entity519 , although the ultimate efficiency of both pathways is comparable. In addition, both pathways may require @entity10614 -mediated conversion of LC3-I into LC3-II. Therefore, we have defined two autophagy-mediated pathways for the @entity204 of @entity5 cells in @entity519 , which are dependent on @entity10614 , interplayed with ER and mitochondria and tightly regulated by @entity519 status. The findings provide a new evidence that autophagy may inhibit @entity5 cell proliferation through trigger of @entity204 , facilitating the development of novel anti- @entity5 drugs.

title: XXXX -independent autophagy mediates programmed @entity5 cell death through interplays with endoplasmic reticulum and/or mitochondria in colbat chloride-induced @entity519 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity5303 :: ('MESH:C018021', 'Chemical') :: ['cobalt chloride', 'CoCl2']

entities_list: @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxic', 'hypoxia']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['PCD', 'programmed cell death']

answer: @entity8783 :: (8678,Gene) :: ['Beclin-1']


abstract: Zur is a regulator of the high-affinity @entity219 uptake system in many bacteria. In @entity68145 , a putative protein encoded by the open reading frame designated as XC1430 shows 42% @entity535 similarity with the Zur of @entity526 . An XC1430-disrupted mutant 1430nk was constructed by homologous suicide plasmid integration. 1430nk failed to grow in rich medium supplemented with @entity8862 at a concentration of 400 microM and in nonrich medium supplemented with @entity8862 at a concentration of 110 microM, whereas the wild-type strain grew well in the same conditions. In rich medium with 400 microM @entity8862 , 1430nk accumulated significantly more @entity8862 than the wild-type strain. 1430nk showed a reduction in virulence on the host plant Chinese radish (Raphanus sativus L. var. radiculus Pers.) and produced less @entity16290 ( @entity16290 ) than did the wild-type strain in the absence of added @entity219 . These results revealed that XC1430 is a functional member of the Zur regulator family that controls @entity219 homeostasis, @entity16290 production, and virulence in @entity17847 pv. campestris.

title: The @entity219 uptake regulator Zur is essential for the full virulence of XXXX pv. campestris.

entities_list: @entity16290 :: ('MESH:C564877', 'Disease') :: ['extracellular polysaccharide', 'EPS']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity68145 :: ('314565', 'Species') :: ['Xanthomonas campestris pv. campestris 8004']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

answer: @entity17847 :: (339,Species) :: ['Xanthomonas campestris']


abstract: Object The Basic Score for Brain @entity3 (BSBM) proposed by Lorenzoni and colleagues is one of the best grading systems for predicting survival periods after stereotactic radiosurgery (SRS) for brain metastases. However, it includes no brain factors and cannot predict neurological outcomes, such as preservation of neurological function and prevention of @entity16 . Herein, the authors propose a modified BSBM, adding 4 brain factors to the original BSBM, enabling prediction of neurological outcomes, as well as of overall survival, in @entity1 undergoing SRS. Methods To serve as neurological prognostic scores (NPSs), the authors scored 4 significant brain factors for both preservation of neurological function (qualitative survival) and prevention of @entity16 (neurological survival) as 0 or 1 as described in the following: > 10 @entity1313 = 0 or  <= 10 = 1, total @entity5 volume > 15 cm(3) = 0 or  <= 15 cm(3) = 1, MRI findings of localized meningeal dissemination (yes = 0 or no = 1), and neurological symptoms (yes = 0 or no = 1). According to the sum of NPSs, @entity1 were classified into 2 subgroups: Subgroup A with a total @entity11989 of 3 or 4 and Subgroup B with an @entity11989 of 0, 1, or 2. The authors defined the modified BSBM according to the @entity11989 subgroup classification applied to the original BSBM groups. The validity of this modified BSBM in 2838 consecutive @entity1 with brain metastases treated with SRS was verified. Results @entity1 included 1868 with @entity2 (including 1604 with @entity1149 ), 355 of the gastrointestinal tract, 305 of the breast, 176 of the urogenital tract, and 134 with other @entity5 . Subgroup A had 2089 @entity1 and Subgroup B 749. Median overall survival times were 2.6 months in BSBM 0 (382 @entity1 ), 5.7 in BSBM 1 (1143), 11.4 in BSBM 2 (1011) and 21.7 in BSBM 3 (302), and pairwise differences between the BSBM groups were statistically significant (all p < 0.0001). One-year qualitative survival rates were 64.6% (modified BSBM 0A, 204 @entity1 ), 45.0% (0B, 178), 82.5% (1A, 825), 63.3% (1B, 318), 86.4% (2A, 792), 73.7% (2B, 219), 91.4% (3A, 268), and 73.5% (3B, 34). One-year neurological survival rates were 82.6% (0A), 52.4% (0B), 90.5% (1A), 78.1% (1B), 91.1% (2A), 83.2% (2B), 93.9% (3A), and 76.3% (3B), where A and B identify the subgroup. Statistically significant differences in both qualitative and neurological survivals between Subgroups A and B were detected in all BSBM groups. Conclusions The authors' new index, the modified BSBM, was found to be excellent for predicting neurological outcomes, independently of life expectancy, in SRS-treated @entity1 with brain metastases.

title: A new grading system focusing on neurological outcomes for brain metastases treated with stereotactic radiosurgery: the modified Basic Score for Brain XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological death']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['cancer of the lung']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['Metastases']

answer: @entity3 :: (MESH:D009362,Disease) :: ['Metastases']


abstract: UNASSIGNED: Neurogenesis involves generation of new neurons through finely tuned multistep processes such as neural stem cell's (NSC) proliferation, migration, differentiation, and integration into existing neuronal circuitry in the dentate gyrus of the hippocampus and sub-ventricular zone (SVZ). Adult hippocampal neurogenesis is involved in cognitive functions and altered in various @entity179 including @entity195 ( @entity195 ). @entity17979 ( @entity8813 ), an anticonvulsant drug is used for the treatment of @entity302 . However, the effects of @entity8813 on adult hippocampal neurogenesis and underlying cellular and molecular mechanism(s) are still elusive. Herein, we studied the effects of @entity8813 on @entity35 multipotent NSC proliferation and neuronal differentiation, and adult hippocampal neurogenesis in an amyloid beta (Ab) toxin induced @entity35 model of @entity195 like phenotypes. @entity8813 potently induced NSC proliferation and neuronal differentiation in the hippocampal derived NSC in vitro. @entity8813 enhanced NSC proliferation and neuronal differentiation, and reduced Ab toxin mediated @entity137 and @entity179 , leading to behavioral recovery in @entity35 @entity195 model. @entity8813 inhibited Ab mediated suppression of neurogenic and @entity2308 -Wnt/b-catenin pathway gene's expression in the hippocampus. @entity8813 activated the @entity39728 / @entity2308 and Wnt/b-catenin transduction pathways that are known to be involved in the regulation of neurogenesis. Inhibition of the @entity39728 / @entity2308 and Wnt/b-catenin pathways effectively blocked the mitogenic and neurogenic effects of @entity8813 . In silico molecular target prediction docking studies suggest that @entity8813 interacts with @entity2308 , @entity60974 and @entity9096 . Our findings suggest that @entity8813 stimulates NSC proliferation and differentiation in vitro and adult hippocampal neurogenesis via the @entity39728 / @entity2308 and Wnt/b-catenin signaling.

title: @entity17979 induces hippocampal neurogenesis and reverses cognitive deficits in amyloid-b toxin induced Alzheimer's @entity35 model via XXXX / @entity2308 /Wnt/b-catenin pathway.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegeneration', 'neurodegenerative disorders']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic seizure']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

entities_list: @entity17979 :: ('MESH:D005013', 'Chemical') :: ['Ethosuximide']

answer: @entity39728 :: (85243(Tax:10116),Gene) :: ['PI3K']


abstract: OBJECTIVES: The aim of this study was a large scale investigation of @entity5442 -associated circulating miRNA molecules and also determination of expression of these candidate molecules in relation to clinical activity of @entity5442 . METHODS: RNA, containing also miRNAs, was isolated from sera of 28 @entity1 suffering from @entity5442 ( @entity5442 ) and 16 healthy controls. Expression of miRNAs was determined using a miRNA microarray method. Statistical analysis of miRNA expression was carried out using Arraystar software. RESULTS: Our results showed 23 significantly differentially expressed miRNAs. Six miRNAs were differentially expressed in @entity5442 compared to healthy controls. In @entity6017 ( @entity6017 ) we found 3 and in @entity6558 ( @entity6558 ) 6 differentially expressed miRNAs compared to controls. Three miRNAs were up-regulated in @entity1 with highly active disease compared to @entity1 with low disease activity. Furthermore, we found 26 significantly differentially expressed miRNAs in @entity1252 @entity1 compared to @entity5442 , @entity6017 and @entity6558 @entity1 . CONCLUSIONS: This is the first study that comprehensively describes expression levels of circulating miRNAs in serum of @entity1 suffering from @entity5442 . It can be expected that some of these deregulated miRNA molecules are involved in aetiology of @entity5442 and may potentially serve as molecular markers for @entity5442 development or for monitoring of disease activity.

title: Microarray analysis of circulating micro RNAs in the serum of @entity1 with @entity6558 and XXXX reveals a distinct disease expression profile and is associated with disease activity.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6017 :: ('MESH:D003882', 'Disease') :: ['dermatomyositis', 'DM']

entities_list: @entity5442 :: ('MESH:D009220', 'Disease') :: ['IIM', 'myositis', 'idiopathic inflammatory myopathies']

entities_list: @entity6558 :: ('MESH:D017285', 'Disease') :: ['PM', 'polymyositis']

answer: @entity6017 :: (MESH:D003882,Disease) :: ['dermatomyositis']


abstract: Sexual functioning is an important element of quality of life. Many @entity1 experience @entity458 as a result of a @entity0 diagnosis and its treatment. Little is known about the availability and the effectiveness of interventions for @entity458 in this @entity1 population. Six electronic databases were searched using Medical Subject Headings and keywords. Additional hand searching of the references of relevant papers was also conducted. The searches were conducted between October 2010 and January 2011. Papers were included if they evaluated interventions for @entity458 caused as a result of @entity0 or its treatment. Studies were only included if sexual functioning was reported using a @entity1 -reported outcome questionnaire. Studies were excluded if sexual functioning was measured but improving @entity458 was not one of the main aims of the intervention. 3514 papers were identified in the initial search. 21 papers were selected for inclusion. Studies were of mixed methodological quality; 15 randomised trials were identified, many included small sample sizes and the use of non-validated questionnaires. Three main types of interventions were identified: Exercise (2), medical (2) and psycho-educational (17). The psycho-educational interventions included skills-based training such as problem-solving and communication skills, counselling, hypnosis, education and specific sex-therapies. Interventions were delivered to individual @entity1 , @entity1 and their partners (couple-based) and groups of @entity1 . The widespread methodological variability hinders the development of a coherent picture about which interventions work for whom. Tentative findings suggest the most effective interventions are couple-based psycho-educational interventions that include an element of sexual therapy. More methodologically strong research is needed before any intervention can be recommended for clinical practice. Improved screening and classification of @entity458 will ensure interventions can be more effectively targeted to suit individual @entity1 needs.

title: Interventions for XXXX following treatment for @entity0 : a systematic review.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['sexual problems']

answer: @entity458 :: (MESH:D020018,Disease) :: ['sexual problems']


abstract: Clinicopathologic features and clinical outcomes of @entity674 ( @entity674 ) in esophagus are limited, because of the relatively rare incidence of esophageal @entity674 . Therefore, the aim of the current study was to investigate the clinicopathologic features and clinical outcomes of esophageal @entity674 , and to investigate the potential factors that may predict prognosis. @entity2910 cases were obtained from our center and from case reports and clinical studies extracted from MEDLINE. Clinicopathologic features and survivals were analyzed and compared with @entity1820 from our center.The most common location was lower esophagus (86.84%), followed by middle and upper esophagus (11.40% and 1.76%). The majority of esophageal @entity674 were classified as high-risk category (70.83%). Mitotic index was correlated with histologic type, mutational status, and @entity5 size. The 5-year disease-free survival and disease-specific survival were 65.1% and 65.9%, respectively. @entity5 size, mitotic index, and National Institutes of Health risk classification were associated with prognosis of esophageal @entity674 . Only @entity5 size, however, was the independent risk factor for the prognosis of esophageal @entity674 . In comparison to @entity1820 , the distribution of @entity5 size, histologic type, and National Institutes of Health risk classification were significantly different between esophageal @entity674 and @entity1820 . The disease-free survival and disease-specific survival of esophageal @entity674 were significantly lower than that of @entity1820 .The most common location for esophageal @entity674 was lower esophagus, and most of the esophageal @entity674 are high-risk category. @entity5 size was the independent risk factor for the prognosis of esophageal @entity674 . Esophageal @entity674 differ significantly from @entity1820 in respect to clinicopathologic features. The prognosis of esophageal @entity674 was worse than that of @entity1820 .

title: Clinicopathologic Features and Clinical Outcomes of Esophageal Gastrointestinal Stromal XXXX : Evaluation of a Pooled Case Series.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor']

entities_list: @entity2910 :: ('MESH:D004941', 'Disease') :: ['Esophageal GIST']

entities_list: @entity1820 :: ('MESH:D005770', 'Disease') :: ['gastric GISTs']

entities_list: @entity674 :: ('MESH:D046152', 'Disease') :: ['GISTs', 'gastrointestinal stromal tumors']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Tumor']


abstract: OBJECTIVE: The aim of this study was to determine the efficacy and tolerability of @entity10748 extended release (ER) in @entity1 with @entity1643 ( @entity1643 ) with or without a neuropathic component. DESIGN: This was a post hoc analysis of data from a multicenter, double-blind, placebo-controlled clinical trial using a randomized withdrawal design, performed in @entity1 with moderate to severe chronic @entity1643 . @entity1 achieving stable doses of @entity10748 ER during a 2- to 4-week conversion and titration phase were randomized to continue treatment with @entity10748 ER or taper-down to placebo during a 12-week double-blind phase. The primary efficacy outcome was the mean change in 11-point Numeric Rating Scale (NRS) @entity158 intensity score from randomization to the final visit of the double-blind phase. Tolerability was assessed by recording adverse events (AEs). Data were analyzed separately for @entity1 with @entity9 . RESULTS: A total of 173 @entity1 with @entity1643 and 94 with @entity1643 were randomized into the double-blind phase. During the conversion and titration phase, mean (SD) NRS scores decreased significantly from 6.5 (1.87) and 6.4 (1.99) at screening to 3.3 (0.98) and 3.2 (1.05), respectively. For both @entity1643 subgroups, @entity1 randomized to @entity10748 ER maintained this improvement over the double-blind treatment period, whereas those randomized to placebo reported significant increase in NRS scores. Across subgroups, the incidence of 1 or more AE was 54 percent to 57 percent in the conversion and titration phase and 47 percent to 55 percent in the double-blind phase. CONCLUSIONS: The results of this study indicate that @entity10748 ER is efficacious and generally well tolerated in the management of @entity1 with @entity9 .

title: XXXX extended release for neuropathic and non-neuropathic/nociceptive @entity1643 : A post hoc analysis of data from a randomized, multicenter, double-blind, placebo-controlled clinical trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['neuropathic LBP', 'chronic low back pain', 'LBP', 'non-neuropathic/nociceptive LBP']

entities_list: @entity10748 :: ('MESH:D004091', 'Chemical') :: ['hydromorphone']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['non-neuropathic and neuropathic LBP', 'non-neuropathic and neuropathic chronic LBP']

answer: @entity10748 :: (MESH:D004091,Chemical) :: ['Hydromorphone']


abstract: OBJECTIVE: To study the role of tranilast in the pathogenesis of @entity82 in @entity2401 . METHODS: Seventy-two BALB/C @entity19 were randomly divided into control, model and intervention groups (n=24 each). @entity19 in the model and intervention groups were infected with Coxsackievirus B3 to induce @entity2401 . The intervention group was given with tranilast (200 mg/kg) by gavage until sacrifice for sampling, while the other two groups were administered with the same volume of normal saline. Cardiac tissues were obtained from 8 @entity19 on 7, 14 and 28 days after modeling. The mast cell number was observed by @entity11979 staining and @entity32341 staining. The cardiac tissues were stained with @entity1710 and @entity1711 as well as masson trichrome to observe the pathological changes in cardiac tissues. The mRNA and protein expression of osteopontin and transforming growth factor-b1 was measured by RT-PCR and immunohistochemistry respectively. RESULTS: In the model group, the mRNA and protein expression of osteopontin reached the highest level on the 7th day, decreasing from the 14th day, and became to the least on the 28th day; while the expression of @entity641 increased from the 7th day, reaching a peak on the 14th day, and decreased slightly on the 28th day. The mRNA and protein expression of @entity641 and @entity1189 was lower in the intervention group than the model group (P<0.05), but higher than the control group (P<0.05). The expression of @entity1189 mRNA was positively correlated to the number of mast cells. CONCLUSIONS: Tranilast can reduce @entity296 by decreasing the number of mast cells, inhibiting the expression of @entity641 and @entity1189 .

title: [Effect of tranilast on @entity296 in @entity19 with XXXX ].

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['myocardiac fibrosis']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial fibrosis']

entities_list: @entity11979 :: ('MESH:D014048', 'Chemical') :: ['toluidine blue']

entities_list: @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin']

entities_list: @entity2401 :: ('MESH:D009205', 'Disease') :: ['viral myocarditis']

answer: @entity2401 :: (MESH:D009205,Disease) :: ['viral myocarditis']


abstract: BACKGROUND: Muscle @entity1674 (TG) are known to be a source of energy during submaximal exercise. OBJECTIVE: The aim of this study was to assess whether an index of muscle fat content is related to maximal fat oxidation rate (FATOXmax) in 58 @entity28 @entity1 (mean age 46.0+/-0.8 (s.e.) y, body weight 96.4+/-1.4 kg, percentage fat: 31.9+/-0.5%) [corrected]. DESIGN: FATOXmax was defined as the highest value of fat oxidation rate, measured by indirect calorimetry, while walking on a treadmill (4.3 km/h) at three different slopes: 0% (40+/-1% of VO2max), 3% (47+/-1% of VO2max) and 6% (58+/-1% of VO2max). @entity1386 ( @entity1386 ) and fat mass (FM) were measured with the underwater technique and scans were obtained by computed tomography (CT) at the mid thigh level to assess areas of adipose tissue within skeletal muscle, ie deep adipose tissue (DAT), @entity1386 ( @entity1386 ), skeletal muscle (M) and low attenuation skeletal muscle (LAM, range of attenuation values: 0-34 Hounsfield units). LAM and DAT were used as indices of skeletal muscle fat content. RESULTS: FATOXmax, adjusted for age, was correlated with @entity1386 (r=0.26, P<0.05), LAM (r=0.29, P<0.05), abdominal visceral adipose tissue (r=0.30, P<0.05) and plasma free @entity844 (FFA) levels (r=0.33, P<0.05) but not with @entity1386 (r=0.03) and DAT (r=0.21) [corrected]. In a stepwise linear multiple regression, plasma FFA, age and LAM significantly predicted FATOXmax (r2=0.27). Each independent variable explained about 9% of the FATOXmax variance. CONCLUSION: LAM makes a significant but weak contribution to the modulation of fat oxidation during submaximal exercise in @entity28 @entity1 .

title: Skeletal muscle low attenuation area and maximal fat oxidation rate during submaximal exercise in XXXX individuals.

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triacylglycerols']

entities_list: @entity1386 :: ('MESH:D018205', 'Disease') :: ['subcutaneous adipose tissue', 'SAT', 'FFM', 'Fat-free mass']

answer: @entity28 :: (MESH:D009765,Disease) :: ['male obese']


abstract: OBJECTIVES: We quantify patterns in prescription opioid dispensations to individuals who suffered a prescription opioid-related @entity204 . In addition, we examine the relationship between opioid dispensations and prescription opioid-related @entity204 in geographic regions of British Columbia (BC). METHODS: We used population-based administrative data on prescription drug dispensations to identify patterns in prescription opioid dispensations to individuals who suffered a prescription opioid-related @entity204 . We also computed the quantity of prescription opioids dispensed ( @entity1286 equivalents) in small geographic regions in BC from 2004 to 2013. We identified prescription opioid-related @entity204 in these small geographic areas using mortality data from BC Vital Statistics and investigated the relationship between rates of prescription opioid dispensing and rates of prescription @entity204 in small geographic areas in BC by sex. We examined differences in our results when limiting opioid dispensations to strong opioids and weak opioids. RESULTS: Many individuals who suffered a prescription opioid-related @entity204 did not have an active opioid prescription in the 60 days before @entity204 (46% of @entity1 and 71% of @entity1 ). Rates of prescription opioid dispensing and opioid-related @entity204 vary substantially across geographic regions in BC. The area-level relationship between rate of prescription opioid dispensing and rate of unintentional prescription opioid-related @entity204 is positive and statistically significant for both @entity1 and @entity1 (P<0.001). This relationship holds when opioid prescribing is limited to strong opioids. CONCLUSION: Targeted efforts to reduce high levels of opioid prescribing in BC, particularly dispensations of strong opioids and @entity10425 , may substantially reduce opioid-related harms.

title: Geographic Variations in Prescription Opioid Dispensations and Deaths Among XXXX and @entity1 in British Columbia, Canada.

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths', 'opioid death', 'death']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

answer: @entity1 :: (9606,Species) :: ['Women']


abstract: The half-Fourier acquisition single-shot @entity9468 (HASTE) sequence allows for heavily T2-weighted images, and the inversion recovery (IR)-HASTE sequence represents the T1 value of the tissue in a very short time. This study was undertaken to determine whether characterizing focal @entity409 can be made by combination with these very fast sequences. Seventy-four @entity1 (33 @entity45 , 28 @entity2695 , and 33 malignant solid liver masses [15 metastatic @entity5 , 14 @entity157 , and 4 @entity201 ) underwent dynamic CT and breath-hold abdominal MRI using @entity9468 ( @entity9468 ), HASTE, and IR-HASTE sequences with variable T1 values on a 1.5-T MR unit. The imaging time for each slice was 2 seconds for HASTE imaging and 2 to 4 seconds for IR-HASTE imaging. Lesion detection and qualitative characterization were evaluated. Quantitative analysis was performed by measuring the contrast-to-noise ratios (CNRs) as well as visual analysis. The inversion time (TI) nulling values were also statistically analyzed. All @entity5409 were detected on both @entity9468 and HASTE imagings. For solid lesions, @entity9468 failed to detect one small solid lesion and HASTE sequence failed to detect three lesions. With HASTE sequences, all @entity45 and @entity2695 were markedly hyperintense in comparison with malignant solid masses. CNRs of @entity2695 or @entity45 were significantly higher than those of malignant solid masses (P < .01), and there was no overlap. The TI nulling value was 1,100+/-100 msec for @entity2695 , 1,900+/-110 msec for @entity45 , and 740+/-140 msec for malignant solid masses. There was no overlap between the TI nulling values of @entity2695 and @entity45 (P < .01). By combining the CNR from the HASTE sequence and the TI nulling value from the IR-HASTE sequence, complete discrimination among malignant solid masses, @entity2695 , and @entity96 could be made. Application of HASTE (representing T2 values) and IR-HASTE (representing T1 values) sequences provided a rapid and reliable imaging method for characterizing focal @entity409 without the use of contrast medium.

title: Characterization of focal @entity409 with half-fourier acquisition single-shot XXXX (HASTE) and inversion recovery (IR)-HASTE sequences.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5409 :: ('MESH:D052177', 'Disease') :: ['cystic lesions']

entities_list: @entity2695 :: ('MESH:D006391', 'Disease') :: ['hemangiomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['cysts of the liver']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver lesions']

entities_list: @entity201 :: ('MESH:D018281', 'Disease') :: ['cholangiocarcinomas']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinomas']

entities_list: @entity9468 :: ('MESH:D014717', 'Disease') :: ['turbo-spin-echo', 'TSE']

answer: @entity9468 :: (MESH:D014717,Disease) :: ['turbo-spin-echo']


abstract: AIMS: Dual therapy comprising @entity24778 for mobilization of bone marrow-derived progenitor cells (BMPCs), with simultaneous pharmacological inhibition of @entity33559 for enhanced myocardial recruitment of circulating BMPC via the SDF-1a/ @entity9843 -axis, has been shown to improve survival after @entity583 ( @entity583 ). Using an innovative method to provide non-invasive serial in vivo measurements and information on metabolic processes, we aimed to substantiate the possible effects of this therapeutic concept on @entity299 after @entity583 using @entity8983 positron emission tomography (FDG-PET). METHODS AND RESULTS: @entity583 was induced in C57BL/6 @entity19 by performing surgical ligation of the left anterior descending artery in these @entity19 . Animals were then treated with granulocyte-colony stimulating factor + @entity12350 ( @entity1412 ) or placebo for a duration of 5 days following @entity583 . From serial PET scans, we verified that the @entity1188 size in @entity1412 -treated @entity19 (n = 13) was significantly reduced at Day 30 after @entity583 when compared with the @entity19 receiving placebo (n = 10). Analyses showed a normalized FDG uptake on Day 6 in @entity1412 -treated @entity19 , indicating an attenuation of the cardiac inflammatory response to @entity583 in treated animals. Furthermore, flow cytometry showed a significant increase in the anti-inflammatory M2-macrophages subpopulation in @entity1412 -treated animals. In comparing @entity1412 treated with placebo animals, those receiving @entity1412 -therapy showed a reduction in @entity1283 and @entity5988 , which indicates the beneficial effect of @entity1412 treatment on @entity299 . Remarkably, flow cytometry and immunohistochemistry showed an increase of myocardial c-kit positive cells in treated @entity19 (n = 12 in both groups). CONCLUSION: Using the innovative method of micro-PET for non-invasive serial in vivo measurements of metabolic myocardial processes in @entity19 , we were able to provide mechanistic evidence that @entity1412 therapy improves cardiac regeneration and reduces adverse remodelling after @entity583 .

title: FDG-PET reveals improved cardiac regeneration and attenuated adverse remodelling following XXXX + @entity24778 therapy after @entity583 .

entities_list: @entity5988 :: ('MESH:C565277', 'Disease') :: ['left ventricular dilatation']

entities_list: @entity1283 :: ('MESH:D006332', 'Disease') :: ['myocardial hypertrophy']

entities_list: @entity12350 :: ('MESH:C496398', 'Chemical') :: ['Sitagliptin']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac remodelling']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

entities_list: @entity8983 :: ('CHEBI:49134', 'Chemical') :: ['2-deoxy-2-[18F]fluoro-d-glucose']

answer: @entity12350 :: (MESH:C496398,Chemical) :: ['Sitagliptin']


abstract: BACKGROUND: Due to the painful nature of childbirth and its maternal and neonatal complications, the @entity1 needs support in this phase of their life. Increased knowledge and skills during pregnancy prepares pregnant mothers for labor and leads to promoted health. AIM: This study was designed to evaluate the effectiveness of "prenatal education" on the process of childbirth. SUBJECTS AND METHODS: This clinical trial was conducted on 195 pregnant @entity1 , that is, control group (N = 132) and case group (N = 63) attending health centers in Amol-Iran from 20 weeks of gestation age during 2012. Case group members attended in "prenatal education" class and the control group only received routine care. Data were collected through demographic questionnaire, standard @entity148 , and a checklist related to childbirth information, and intensity of @entity158 based on visual analogue scale and McGill scales. The data were analyzed by Statistical Package for the Social Sciences software using t-test and Chi-square test. RESULTS: The result of this study showed that the parent with a high level of education was more interested to @entity1 in prenatal classes. The anxiety level in case group (who received education) was 14.47 (4.69) and in control group it was 16 (4.86), (P < 0.001) the @entity158 intensity in case group was 85.68 (1.85) and in control group was 90.99 (14.72) (P = 0.03), intervention on labor such episiotomy was 39 %66.1 (39/63) in case group and 80 %72.8 (80/132) in control group (P = 0.01) and cesarean section was 13 %17.1 (13/63) in case group and 58 %32.2 (58/132) in control group (P = 0.01). CONCLUSIONS: According to findings of this study, the prenatal education and psychological support are beneficial for mothers during pregnancy and labor. Therefore, it is recommended for educating all the pregnant @entity1 .

title: The Effectiveness of Prenatal Intervention on @entity158 and XXXX during the Process of Childbirth-Northern Iran: Clinical Trial Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'woman', 'participant']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['hospital anxiety questionnaire']

answer: @entity148 :: (MESH:D001008,Disease) :: ['Anxiety']


abstract: UNASSIGNED: @entity421 ( @entity421 ), a highly aggressive primary @entity3478 , belongs to the most common @entity5 in growing @entity1 . Since specific molecular targets for @entity421 treatment remain to be identified, surgical resection combined with multimodal (neo-)adjuvant chemotherapy is still the only way to help respective individuals. We have previously identified the protein @entity4149 phosphatase Rptp   as a marker of terminally differentiated osteoblasts, which negatively regulates their proliferation in vitro. Here we have addressed the question if Rptp   can function as a @entity5 suppressor protein inhibiting @entity421 development in vivo. We therefore analyzed the skeletal phenotype of @entity19 lacking @entity68863 , the gene encoding Rptp   on a @entity5 -prone genetic background, i.e. @entity186 -heterozygosity. By screening a large number of 52 week old @entity186 -heterozygous @entity19 by contact radiography we found that @entity68863 -deficiency significantly enhanced @entity421 development with 19% of the @entity19 being affected. The @entity5 in @entity68863 -deficient @entity186 -heterozygous @entity19 were present in different locations (spine, long bones, ribs), and their @entity421 nature was confirmed by undecalcified histology. Likewise, cell lines derived from the @entity5 were able to undergo osteogenic differentiation ex vivo. A comparison between @entity68863 -heterozygous and @entity68863 -deficient cultures further revealed that the latter ones displayed increased proliferation, a higher abundance of @entity4149 -phosphorylated proteins and resistance towards the influence of the growth factor @entity13438 . Our findings underscore the relevance of Rptp   as an attenuator of proliferation in differentiated osteoblasts and raise the possibility that activating Rptp  -dependent signaling could specifically target osteoblastic @entity5 cells.

title: The Protein @entity4149 Phosphatase Rptp   Suppresses XXXX Development in @entity186 -Heterozygous @entity19 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity3478 :: ('MESH:D001859', 'Disease') :: ['bone tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'solid tumors']

entities_list: @entity421 :: ('MESH:D012516', 'Disease') :: ['Osteosarcoma', 'OS']

answer: @entity421 :: (MESH:D012516,Disease) :: ['Osteosarcoma']


abstract: BACKGROUND: Perioperative antiplatelet agents potentially increase @entity548 after non-ST-segment elevation (NSTE) @entity1187 ( @entity1187 ). The @entity8781 antagonist vorapaxar reduced cardiovascular events and was associated with increased @entity548 versus placebo in NSTE @entity1187 , but its efficacy and safety in noncardiac surgery (NCS) remain unknown. We aimed to evaluate @entity63 , @entity548 , and long-term outcomes of vorapaxar in NCS after NSTE @entity1187 . METHODS AND RESULTS: In the TRACER trial, 2202 (17.0%) @entity1 underwent major or minor NCS after NSTE @entity1187 over 1.5 years (median); continuing study treatment perioperatively was recommended. The primary @entity63 end point for this analysis was @entity65 , @entity583 , stent @entity715 , or urgent revascularization within 30 days of NCS. Safety outcomes included 30-day NCS @entity548 and GUSTO moderate/severe @entity548 . Overall, 1171 vorapaxar and 1031 placebo @entity1 underwent NCS. Preoperative @entity117 and @entity1747 use was 96.8% versus 97.7% (P=0.235) and 89.1% versus 86.1% (P=0.036) for vorapaxar versus placebo, respectively. Within 30 days of NCS, no differences were observed in the primary @entity63 end point between vorapaxar and placebo groups (3.4% versus 3.9%; adjusted odds ratio 0.81, 95% CI 0.50 to 1.33, P=0.41). Similarly, no differences in NCS @entity548 (3.9% versus 3.4%; adjusted odds ratio 1.41, 95% CI 0.87 to 2.31, P=0.17) or GUSTO moderate/severe @entity548 (4.2% versus 3.7%; adjusted odds ratio 1.15, 95% CI, 0.72 to 1.83, P=0.55) were observed. In a 30-day landmarked analysis, NCS @entity1 had a higher long-term risk of the @entity63 end point (adjusted hazard ratio 1.62, 95% CI 1.33 to 1.97, P<0.001) and GUSTO moderate/severe @entity548 (adjusted hazard ratio 5.63, 95% CI 3.98 to 7.97, P<0.001) versus @entity1 who did not undergo NCS, independent of study treatment. CONCLUSION: NCS after NSTE @entity1187 is common and associated with more @entity63 outcomes and @entity548 . Vorapaxar after NSTE @entity1187 was not associated with increased perioperative @entity63 or @entity548 events in @entity1 undergoing NCS.

title: Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome XXXX Undergoing Noncardiac Surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndromes']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

entities_list: @entity1747 :: ('MESH:C446540', 'Chemical') :: ['thienopyridine']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity8781 :: ('2149', 'Gene') :: ['protease-activated receptor 1']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular death']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: OBJECTIVES: To assess the feasibility and the safety of conservative surgery to treat spermatic @entity602 . METHODS: @entity1 undergoing inguinoscrotal exploration in 10 different Urological Centers with diagnosis of @entity1822 were enrolled. Preoperative evaluation included physical examination, Scrotal US, Abdominal CT and Scrotal MRI in selected cases. @entity1 underwent organ sparing surgery or orchiectomy in case of intraoperative FSE was positive for a local infiltration. Data collected were: age, presence of infiltration, length of the lesion, number of lesions, definitive histological outcome, pre and postoperative @entity251 level. Follow up was performed with abdomen CT scan and scrotal US. RESULTS: From January 2007 to December 2013, 23 @entity1 (mean age: 64.7  yrs) were diagnosed with spermatic @entity602 . Each @entity1 underwent scrotal US. 10 @entity1 underwent radical orchiectomy and 13 @entity1 underwent conservative surgery. Mean follow up was 36.5 months. 5 @entity1 (21.7%) developed a recurrent disease, 18 @entity1 (78.3%) had a negative follow up (mean time: 40.8 months). Statistical analysis reveals that there is a significant correlation between number of lesions, length of the lesions and recurrent disease. CONCLUSIONS: Spermatic @entity602 is a rare disease. Conservative surgical treatment of spermatic @entity602 is a feasible therapeutic option for small, single and not infiltrating lesion.

title: Feasibility and safety of conservative surgery for the treatment of spermatic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1822 :: ('MESH:D007890', 'Disease') :: ['leiomyosarcoma']

entities_list: @entity602 :: ('MESH:D013118', 'Disease') :: ['cord leiomyosarcoma']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

answer: @entity602 :: (MESH:D013118,Disease) :: ['cord leiomyosarcoma']


abstract: Adult @entity3392 were reared up to eight weeks in control water or in water containing @entity70374 (AP) at measured @entity13756 concentrations of 18 (environmentally relevant, high) and 677 ppm. Groups of eight females were paired with four males on a weekly basis to assess AP effects on spawned egg volume, an index of reproductive performance. All treatments were applied to four to five spawning replicates. At 677 ppm, spawn volume was reduced within one week and became negligible after four weeks. At 18 ppm, spawn volume was unaffected even after eight weeks. Also, @entity13756 at 18 ppm did not affect percentage egg fertilization. Fish were collected at the end of the exposures (677 ppm, four weeks; control and 18 ppm, eight weeks) for whole-body @entity13756 content and thyroid histopathological analysis. Fish @entity13756 levels were about one-hundredth of those of treatment water levels, indicating that waterborne @entity13756 does not accumulate in whole fish. At 677 ppm for four weeks, @entity13756 caused thyroid follicle cell (nuclear) @entity1184 and @entity7499 , whereas at 18 ppm for eight weeks, its effects were more pronounced and included @entity1184 , @entity7499 , @entity1373 , and colloid depletion. In conclusion, an eight-week exposure of adult @entity3392 to 18 ppm @entity13756 (high environmentally relevant concentrations) affected the histological condition of their thyroid follicles but not their reproductive performance. The effect of 677 ppm @entity13756 on reproduction may be due to @entity137 . Further research is needed to determine if AP at lower environmentally relevant concentrations also affects the thyroid follicles of @entity3392 .

title: Effects of @entity70374 on the reproductive performance and thyroid follicle histology of XXXX .

entities_list: @entity70374 :: ('MESH:C053506', 'Chemical') :: ['ammonium perchlorate']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['extrathyroidal toxicity']

entities_list: @entity7499 :: ('MESH:D016510', 'Disease') :: ['angiogenesis']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia']

entities_list: @entity13756 :: ('MESH:C494474', 'Chemical') :: ['perchlorate']

answer: @entity3392 :: (7955,Species) :: ['zebrafish']


abstract: BACKGROUND: The long-term risk-benefit effect of occasional and regular use of low-dose @entity117 ( <= 100 mg per day) in primary prevention of @entity455 and @entity5 was calculated. METHODS: One representative database of 1,000,000 @entity1 from Taiwan's National Health Insurance scheme in 1997-2000 was used. The potential study subjects were those aged 30-95 years, were found not to have been prescribed @entity117 before 1 January 2000, but to have first been prescribed low-dose @entity117 ( <= 100 mg per day) after that date, and were followed up to 31 December 2009. @entity1 prescribed low-dose @entity117 < 20% during the study period were considered occasional users and those prescribed >=  80% regular users. After the propensity-score matching, rate differences of @entity548 , @entity63 , and @entity5 between these users were calculated their net clinical risk. RESULTS: 1,720 pairs were analyzed. During the study period, @entity548 and @entity63 occurred in 25 (1.45%) and 67 @entity1 (3.90%) in occasional users and 69 (4.01%) and 100 @entity1 (5.81%) in regular users, whereas @entity5 occurred in 32 @entity1 (1.86%) in occasional users and 26 @entity1 (1.51%) in regular users. The crude and adjusted net clinical risks of low-dose @entity117 use between the two frequency of users (>=  80% vs. < 20%) were 4.12% (95% CI = 2.19%, 6.07%; P < 0.001) and 3.93% (95% CI = 2.01%, 5.84%; P < 0.001). CONCLUSIONS: A long-term regular use of low-dose @entity117 might not be better than occasional use in the primary prevention against @entity455 and @entity5 . This article is protected by copyright. All rights reserved.

title: A Long-term Risk-Benefit Analysis of Low-dose XXXX in Primary Prevention.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['major vascular diseases', 'vascular diseases']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer']

answer: @entity117 :: (MESH:D001241,Chemical) :: ['Aspirin']


abstract: BACKGROUND: @entity1140 is a potent immunosuppressive agent that provides higher freedom from acute and chronic rejection than @entity205 after liver transplantation (LTx). Initially, a @entity134 -free state was observed in about 70% of @entity1 at 1 year; this did not change over the next 5 years. The present study identifies the various reasons why the remaining 30% of adult @entity1 still require @entity230 even after 5 years after successful LTx. METHOD: Eight hundred thirty-four consecutive @entity1 who underwent LTx between August 1989 and December 1992 were included in this study. Four hundred ninety-nine @entity1 were alive in January 1999 and were available for this study. The dose of @entity134 and the reason for @entity134 use were retrospectively determined from the clinical records. RESULTS: Three hundred sixty-five @entity1 (73.1%) were off @entity134 , whereas 134 @entity1 (26.9%) were receiving @entity229 (mean dose was 6.4+/-3.7 mg/day) at the time of the study. Four hundred and eight-four @entity1 (97%) were off @entity229 at some time after LTx; however, in 119 (23.8%) @entity1 , @entity230 were reintroduced. Fifteen @entity1 (3%) continued to receive @entity229 ; eight receive @entity229 due to reluctance of the local physician to withdraw the medication; in five @entity1 , the @entity229 was not withdrawn because these @entity1 were on @entity205 ; in the remaining two @entity1 , repeated attempts to withdraw @entity134 resulted in a rise in liver function test. In the 49 (36.6%) of 119 @entity1 in whom the @entity134 was reintroduced, it was restarted secondary to pathologically proven or clinically suspected rejection (group I). In five @entity1 @entity134 was reintroduced for @entity409 after being off immunosuppression for treatment of a @entity1071 . Six @entity1 were noncompliant with their immunosuppressive medication, and the @entity134 was reintroduced to control rejection. @entity230 were reintroduced in 30 @entity1 (22.4%) for recurrence of original disease: @entity2835 (n= 19), sclerosing @entity255 (n=6), and @entity775 (n=5) (group II). In 24 @entity1 (20.2%), @entity230 were reintroduced to lower the dose of @entity1140 secondary to nephrotoxicity. Six of these @entity1 received kidney transplantation (group III). In 16 @entity1 (13.4%) the @entity134 was reintroduced for concomitant medical problems, consisting of @entity31 (n=6), @entity1887 (n=5), @entity1503 (n=3), @entity1909 (n=1), and @entity309 (n=1) (group IV). CONCLUSION: Ninety-seven percent of @entity1 under @entity1140 were weaned off @entity134 ; however, 23.8% required @entity134 reintroduction for late rejection, recurrence of @entity792 (es), @entity8 , or the concomitant presence of other medical conditions. Although the use of other immunosuppressive agents may reduce the rate of reintroduction of @entity134 , long-term sustained freedom from @entity134 may not be possible in all @entity1 under @entity1140 secondary to these conditions.

title: Reasons for long-term use of XXXX in primary adult liver transplantation under @entity1140 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2835 :: ('MESH:D008105', 'Disease') :: ['primary biliary cirrhosis']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment']

entities_list: @entity1071 :: ('MESH:D008232', 'Disease') :: ['posttransplantation lymphoproliferative disorder']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity1887 :: ('MESH:D000309', 'Disease') :: ['adrenal insufficiency']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['abnormal liver function']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ["ulcerative/Crohn's colitis"]

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological disorders']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune process']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['Tacrolimus', 'tacrolimus']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['Steroids', 'steroids']

entities_list: @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']

entities_list: @entity775 :: ('MESH:D019693', 'Disease') :: ['autoimmune hepatitis']

answer: @entity134 :: (CHEBI:35341,Chemical) :: ['steroid']


abstract: This study examines proliferative activity in @entity5 cells of @entity1 with histologically documented invasive @entity0 treated with magnetic resonance-guided interstitial laser photocoagulation (MR-GILP). Immunohistochemical marker for @entity1364 ( @entity1364 ), a nuclear protein abundant in actively proliferating cells, is used. The study demonstrates the effectiveness of MR-GILP in ablating @entity5 cells of infiltrating @entity0 . The diagnosis of infiltrating @entity0 was confirmed by core needle biopsies. Using a specially designed magnetic resonance imaging (MRI) device, rotating delivery of excitation off-resonance (RODEO), @entity5 were measured ranging from 1.8 to 4.0 cm in greatest dimension. Seven @entity406 -fixed, @entity982 -embedded archival tissues from seven @entity1 with infiltrating @entity189 , status post-MR-GILP, were analyzed. Using @entity1364 immunoperoxidase (Biomeda Corp.), the proliferative capability of the remaining @entity5 cells around the focus of laser photocoagulation was determined. The lesions were digitally acquired using a Nikon Eclipse E800 microscope with an automated stage. Images were analyzed using Cool SNAP image editing software (version 1.0). Appropriate thresholds were set for positive staining and limited concentric radial measurements of equal area between all samples were compared at radial millimeter intervals from the center of laser ablation. The integrated area occupied by @entity1364 -positive cells per radial millimeter from the charcoal site (the center of the laser) increased as the distance from this site increased (a mean average at each radial measurement revealed: at the 1 mm radius the positive integrated area was 0.0024 mm2; at 2 mm, 0.0145 mm2; at 3 mm, 0.0351 mm2; at 4 mm, 0.0696 mm2; at 5 mm, 0.1025 mm2; and at 6 mm, 0.1263 mm2). MR-GILP is an effective mean of ablating @entity0 . This treatment option may represent an alternative to lumpectomy for a single lesion < or =1 cm, or make @entity1 with two separate lesions eligible for lumpectomy.

title: Assessment of XXXX activity using digital image analysis in @entity0 following magnetic resonance-guided interstitial laser photocoagulation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1364 :: ('5111', 'Gene') :: ['proliferating cell nuclear antigen', 'PCNA']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma', 'breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']

answer: @entity1364 :: (5111,Gene) :: ['proliferating cell nuclear antigen']


abstract: Conventional adhesive systems use three different agents--an enamel conditioner, a primer solution, and an adhesive resin--during the bonding of orthodontic brackets to enamel. A unique characteristic of some new bonding systems in operative dentistry is that they combine the conditioning and priming agents into a single application. Combining conditioning and priming saves time and should be more cost-effective to the clinician and indirectly to the @entity1 . The purpose of this study was to assess and compare the effects of self-etching primers, including a @entity1388 -releasing primer, on the shear bond strength of orthodontic brackets. The brackets were bonded to extracted @entity1 teeth according to one of four protocols. In group 1 (control), teeth were etched with 37% @entity8718 ; after the sealant was applied, the brackets were bonded with Transbond XT (3M Unitek, Monrovia, @entity2948 ) and light cured for 20 seconds. In group 2, a self-etch acidic primer (3M ESPE, St Paul, Minn) was applied as suggested by the manufacturer, and the brackets were then bonded with Transbond XT as in the first group. In group 3, an experimental self-etch primer EXL #547 (3M ESPE) was applied to the teeth as suggested by the manufacturer, and the brackets were then bonded as in groups 1 and 2. In group 4, a @entity1388 -releasing self-etch primer, One-Up Bond F (J. Mortia, USA Inc. Irvine, @entity2948 ) that also has a novel dye-sensitized photo polymerization initiator system was applied as suggested by the manufacturer, and the brackets were then bonded as in the other groups. The present in vitro findings indicated that the shear bond strengths of the four groups were significantly different (P = .001). Duncan multiple range tests indicated that One-Up Bond F (mean +/- SD strength, 5.1+/-2.5 MPa) and Prompt L-Pop (strength, 7.1+/-4.4 MPa) had significantly lower shear bond strengths than both the EXL #547 self-etch primer (strength, 9.7+/-3.7 MPa) or the @entity8718 etch and the conventional adhesive system (strength, 10.4+/-2.8 MPa).

title: Effect of a XXXX -releasing self-etch acidic primer on the shear bond strength of orthodontic brackets.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patient']

entities_list: @entity8718 :: ('MESH:C030242', 'Chemical') :: ['phosphoric acid']

entities_list: @entity1388 :: ('MESH:D005459', 'Chemical') :: ['fluoride']

answer: @entity1388 :: (MESH:D005459,Chemical) :: ['fluoride']


abstract: PURPOSE: To determine the prevalence rates and associated characteristics of @entity1 who have ocular surface, ocular adnexal, and lacrimal complications associated with the systemic use of the @entity5 chemotherapeutic agent @entity1487 ( @entity1487 ). METHODS: An exposure-based cohort study was designed. Adult @entity1 who had completed at least 3 months of systemic @entity1487 therapy within the past 5 years were eligible for enrollment. Study subjects had a detailed medical history taken with emphasis on preexisting conditions known to be associated with the development of ocular surface, ocular adnexal, and lacrimal complications. An ocular examination was then performed. A complete nasolacrimal system evaluation was performed if symptoms or findings were identified. The prevalence was then determined for each ocular symptom and each ocular finding identified that was not present pretreatment. An exploratory analysis was then performed to identify @entity1 characteristics that might influence the likelihood of developing any of the above complications. RESULTS: Fifty-two @entity1 were enrolled in the study. The prevalence rates of the following ocular abnormalities were calculated: ocular irritation, 5.8%; @entity14985 , 3.8%; @entity2024 , 3.8%; @entity1036 , 3.8%; @entity1909 , 5.8%; cicatricial ectropion, 1.9%; tearing, 26.9%; punctal-canalicular @entity850 , 5.8%; and blurred vision, 11.5%. Blacks had tearing at a significantly higher rate when compared with whites (P = 0.022, 2-sided Fisher exact test). Three @entity1 had permanent complications that will require surgery for correction. Of the 7 @entity1 who had a single abnormality, 6 had tearing and one had @entity1909 . All of the 8 @entity1 who had multiple findings had tearing as one of their abnormalities. CONCLUSIONS: Ninety-three percent of the @entity1 who had an @entity735 had tearing as one of the complications. @entity1 who are receiving systemic @entity1487 and begin to tear should have an ocular examination, looking for ocular surface, ocular adnexal, and lacrimal complications.

title: Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1036 :: ('MESH:D007634', 'Disease') :: ['keratitis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity14985 :: ('MESH:D001762', 'Disease') :: ['blepharitis']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['ocular abnormality']

entities_list: @entity2024 :: ('MESH:D003231', 'Disease') :: ['conjunctivitis']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity1909 :: ('MESH:D003872', 'Disease') :: ['eyelid dermatitis']

answer: @entity1487 :: (MESH:D005472,Chemical) :: ['5-fluorouracil']


abstract: Because @entity528 is triggered by several parallel mechanisms, a combination of drugs active against individual death-promoting mechanisms may have synergistic effects. @entity10025 is a noncompetitive @entity143 antagonist with anti-inflammatory effects and @entity11933 is a @entity29254 antioxidant. Therefore, we explored whether their combined use results in smaller @entity1188 volumes as compared with their individual administration. @entity35 underwent @entity2500 ( @entity2500 ) and were given vehicle, @entity10025 alone, @entity11933 alone, or a combination of @entity10025 and @entity11933 (n = 13 per group) 1 h later. Five animals in each group were evaluated with a motor rating scale 24 h after @entity2500 and the @entity1188 volumes were then measured. The remaining animals were examined with motor and behavioral scales up to 30 days after @entity2500 and their @entity1188 volumes were then determined. Motor disability and water maze latencies at all time points examined and @entity1188 volumes at days 1 and 30 were significantly reduced in all active treatment groups when compared with vehicle. However, no significant differences were observed between the active treatment groups. In conclusions, combination therapy with @entity10025 and @entity11933 does not appear to have additional neuroprotective effects compared to those conferred by each agent alone even when administered at optimal timing and dosing. Therefore, a ceiling neuroprotective effect that is impossible to overcome may exist.

title: Combination of XXXX and @entity11933 in focal cerebral ischemia: is there a ceiling effect?

entities_list: @entity10025 :: ('MESH:C062018', 'Chemical') :: ['dexanabinol', 'Dexanabinol']

entities_list: @entity2500 :: ('MESH:D020244', 'Disease') :: ['PMCAO', 'permanent middle cerebral artery occlusion']

entities_list: @entity29254 :: ('CHEBI:29767', 'Chemical') :: ['nitroxide']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['ischemic neuronal death']

answer: @entity10025 :: (MESH:C062018,Chemical) :: ['dexanabinol']


abstract: OBJECTIVES: To determine the impact of a pediatric donation after @entity204 (DCD) program on organ donation. DESIGN: Retrospective case series. SETTING: A free-standing @entity1 's hospital. @entity1 : All ventilated pediatric intensive care unit @entity1 who died between September 1, 2005 and April 30, 2007. INTERVENTIONS: Institution of a DCD program. MEASUREMENTS AND MAIN RESULTS: Data collected included clinical features, medical eligibility and consent for organ donation, as well as outcome for donation among eligible @entity1 . One hundred ten @entity1 who died in the pediatric intensive care unit and were treated with mechanical ventilation immediately before @entity204 were identified. Thirty-one @entity1 met exclusion criteria, 26 @entity1 were not referred, and 53 @entity1 were evaluated for potential DCD by the organ procurement agency. The majority of @entity1 had @entity519 or @entity130 as their primary diagnosis. Family members initiated discussions regarding donation in 17% of evaluations. Sixty-eight percent of @entity1 were deemed medically ineligible by the organ procurement agency. Of the 17 medically eligible @entity1 , consent for donation was given in 9 cases (53%). Of these, 7 @entity1 (41%) successfully donated; accounting for 37% of organ donors during the study period. Two families gave consent for donation which did not occur; one @entity1 did not die within the required time period and one could not be matched with any recipients. CONCLUSIONS: Although a small percentage of dying @entity1 are eligible for and will undergo DCD, such a program can markedly increase the number of organ donors at a @entity1 's hospital.

title: Impact of a pediatric donation after XXXX program.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'PATIENTS', 'child']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death', 'death']

answer: @entity204 :: (MESH:D003643,Disease) :: ['cardiac death']


abstract: STUDY OBJECTIVES: (1) to develop an indicator of socioeconomic position based on the social standing of the habitat (SSH), that is, the residential building, its immediate surroundings, and local neighbourhood; (2) to assess the relation of SSH to two usual markers of socioeconomic position (education and occupation) and a known, socially determined health outcome ( @entity101 ). DESIGN: Population survey measuring SSH, detailed educational and occupational histories, and blood pressure. The SSH is a standardised assessment of the external and internal aspects of someone's building (or house), and of the characteristics of its immediate surroundings and local neighbourhood. SETTING: A sample of @entity1 to the Bus Sant   survey between 1993 and 1998, in Geneva, Switzerland. @entity1 : 588 @entity1 and @entity1 , aged 35 to 74. MAIN RESULTS: The SSH index was highly reproducible (kappa=0.8). Concordance of SSH with education or occupation was good for @entity1 of either high or low socioeconomic position, but not for those with medium education and/or occupation. There was a higher prevalence of @entity101 in the lowest compared with the highest groups, defined on the basis of education or occupation, but the SSH was the only indicator that showed a higher prevalence of @entity101 among @entity1 in the middle of the social spectrum. CONCLUSIONS: @entity1 of medium education or occupation are heterogeneous with respect to their habitat. Those living in habitats of medium social standing may be most affected by @entity101 but this association could not be revealed on the basis of education and occupation alone. The habitat seems to capture different aspects of the socioeconomic position compared with the usual indicators of social class.

title: Measuring the habitat as an indicator of socioeconomic position: methodology and its association with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'PARTICIPANTS', 'people', 'People', 'men']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: In Germany, 36% of all new chronic dialysis @entity1 have @entity2316 . The majority are type 2 diabetics. Early intervention has the greatest effect. Incipient @entity8 can be diagnosed by evidence of microalbuminuria (30-300 mg albumin/g @entity1011 ). @entity644 on the standard test strip (>300 mg/g) indicates manifest @entity8 followed by progressive @entity177 . Important cofactors for progression are @entity101 , @entity4854 , and smoking. Low normal blood pressure levels (<130/80 mmHg without and <125/75 mmHG with @entity644 ) based on ACE inhibitors/AT1 blockers are the goal. Combination therapies are frequently necessary. This can often reverse microalbuminuria. @entity177 requires special attention (e.g. bone metabolism, @entity417 , @entity520 ). Timely initiation of renal replacement therapy (GFR <15 ml/min) reduces morbidity and mortality. In addition to hemo- and peritoneal dialysis, early kidney and in individual cases of type 1 @entity6 combined kidney/pancreas transplantation is appropriate.

title: [Diagnostics and therapy of XXXX nephrology].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria', 'Proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure', 'Chronic renal failure']

entities_list: @entity520 :: ('MESH:D000138', 'Disease') :: ['acidosis']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetic']


abstract: Recent studies have shown improved efficacy of chemotherapy in @entity1 with @entity135 . Our purpose was to evaluate prospectively the activity of @entity900 plus @entity1487 ( @entity1487 ) in 37 @entity1 with advanced stage @entity135 . There were two groups. Group 1 consisted of 19 previously untreated @entity1 with either T4 or N3 disease. They received 100 mg/m2 @entity900 (days 1 and 28) and 120-hour infusion of 1,000 mg/m2/24 hours @entity1487 (days 1 to 5 and 28 to 32). They subsequently were offered preoperative radiotherapy (RT) and surgery. Group 2 consisted of 18 previously treated @entity1 . They received @entity1487 and @entity900 in the same dosage every 28 days for either recurrent or metastatic disease. It was found that in group 1 there was an 84% response rate (five complete responses (CR) and 11 partial responses (PR) ). Three of those with PR achieved a CR after RT. Seven @entity1 have had RT plus surgery and are disease free at 8 to 27 month follow-up. Six @entity1 (one CR, five PR) refused surgery and progressed within 4 months. In group 2 there was an 11% response rate after two cycles (two PR), three @entity1 had a minimal response (MR, less than 50% response) and received a mean of four cycles of treatment. Three @entity1 with stable disease received a mean of four cycles of chemotherapy until progression. Two of 11 @entity1 who had received previous chemotherapy plus RT showed an MR; nine of these @entity1 had shown a response to their previous chemotherapy. Only one of 14 @entity1 who had RT plus chemotherapy had a PR, and three had MR. Of five @entity1 who had previous surgery, only one had a PR. All five had received chemotherapy as well. It was concluded that @entity1487 plus @entity900 is an effective combination in previously untreated @entity1 . In previously treated @entity1 with recurrent disease, there is a substantially lower response rate.

title: A prospective evaluation of @entity1487 plus @entity900 in XXXX .

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['IV squamous-cell cancer of the head and neck', 'advanced squamous-cell cancer of the head and neck']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5FU', '5-fluorouracil']

answer: @entity135 :: (MESH:D006258,Disease) :: ['advanced squamous-cell cancer of the head and neck']


abstract: INTRODUCTION: Interbody fusion is the gold standard treatment for the management of numerous diseases of the spine. Minimally invasive techniques may be more beneficial than conventional techniques. The main goal of this study was to report the one-year postoperative results of a series of posterior lumbar interbody fusions by a minimally invasive technique in relation to improvement in functional outcome, interbody fusion and morbidity. MATERIALS AND METHODS: Between January 2012 and May 2013, 182 @entity1 treated by minimally invasive posterior @entity2649 ( @entity2649 ) were included in this prospective multicenter study. Clinical assessment was based on a comparison of the preoperative and one-year postoperative Oswestry (ODI), SF-12 and Quebec Scores and the Visual Analog Scale (VAS). Surgical and postoperative follow-up data were evaluated. Radiological assessment was based preoperative and one-year postoperative full spine teleradiographs. Interbody fusion at one-year was systematically evaluated by CT scan. RESULTS: One hundred and eighty-two @entity1 were included, mean age 58.9 years old. Surgery lasted a mean 101minutes, mean preoperative bleeding was 143mL, and  mean radiation exposure was 247.4  cGy/cm(2). The rate of @entity260 was 7.7%. The ODI, the Quebec Score, the SF-12 and the VAS were all significantly improved at one-year (P<0.0001). The rate of fusion was 72.6% at the final follow-up. There was no significant difference in functional outcome between @entity1 with and without fusion. DISCUSSION: The one-year postoperative radiological results and functional outcome of minimally invasive posterior lumbar fusion are satisfactory. The benefits of this minimally invasive approach are mainly found in the first 6 postoperative months. Successful radiological interbody fusion was not correlated to functional outcome at the final follow-up. LEVEL OF EVIDENCE: IV.

title: Minimally invasive posterior XXXX : One-year postoperative morbidity, clinical and radiological results of a prospective multicenter study of 182 cases.

entities_list: @entity2649 :: ('MESH:C563613', 'Disease') :: ['transforaminal lumbar interbody fusion', 'TLIF']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

answer: @entity2649 :: (MESH:C563613,Disease) :: ['transforaminal lumbar interbody fusion']


abstract: BACKGROUND: Clinical stage (c-stage) I @entity1149 ( @entity1149 ) is generally indicated for surgery, however, surgical exploration sometimes reveals @entity1442 , thus resulting in incomplete resection. @entity1 AND METHODS: A total of 645 consecutive @entity1 were investigated in which 347 were diagnosed to have c-stage IA in 347 and 298 were diagnosed to have @entity66 . All cases underwent operation and were investigated for resectability and the cause of an incomplete resection. RESULTS: The c-Stage IA @entity1 included 16.6% of T3/4 and 10.4% of N2 whereas clinical stage IB @entity1 included 14.4% of T3/4 and 18.8% of N2/3. A complete resection was performed in 594 @entity1 (91%). In 347 c-stage IA @entity1 , the complete resection rates were 93% in @entity420 (235/252), 100% in @entity957 (76/76), and 89% in others (17/19). In 298 c-stage IB @entity1 , the complete resection rates were 86% in @entity420 (141/164), 90% in @entity957 (90/100), and 94% in others (31/33). The 5-year survival rates of the c-stage IA and IB @entity1 who underwent a complete resection were 66.4 and 48.3%, respectively. However, the same rates were 18.4 and 14.7% for c-stage IA and IB @entity1 who underwent an incomplete resection. The reasons for an incomplete resection in 54 @entity1 were @entity5 in 38 (70.4%), extranodal invasion of mediastinal nodal metastasis in ten (19%), an incomplete bronchial margin in three (5.6%), and ipsilateral pulmonary metastases in two (3.7%), and ipsilateral adrenal metastasis in one (1.3%). In 13% of the c-stage IB @entity420 , @entity3 was discovered during thoracotomy. CONCLUSIONS: Pleural dissemination was the most frequent cause of an incomplete resection, and its prevalence was high in c-stage IB @entity420 .

title: Operative results of clinical stage I XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['IB disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant pleurisy']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinomas']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['pleural metastasis']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: BACKGROUND: The data supporting the practice of empiric slow pathway ablation (ESPA) in @entity1 with documented @entity4710 ( @entity4710 ) who are non-inducible at electrophysiology study (EPS) is limited. The aim of this study is to assess the efficacy of ESPA in adults. METHODS: A multi-center cohort study of @entity1 who had ESPA between January 2008 and October 2013 was performed. @entity1 were identified by screening sequential @entity4710 ablation procedures. RESULTS: Forty-three (5%) out of 859 @entity4710 ablation procedures were identified as ESPA. The median age was 53 (IQR: 24) years; 63% were female. All @entity1 had pre-EPS documentation of @entity4710 (either strip or ECG). In 23 (53.5%) cases, pre-EPS ECG showed short @entity591 . Thirty-two (74.4%) @entity1 had dual atrioventricular nodal physiology (DAVNP) plus echo beats. Junctional rhythm (JR) as procedural endpoint was noted in 39 (90.7%) @entity1 . In 18 (41.9%) @entity1 , the abolishment of DAVNP was achieved. No complications were encountered. A median follow-up of 17months (range: 6 to 31months) revealed 83.7% (36 of 43) success rate, defined as the absence of pre-procedural symptoms and any documented sustained @entity943 . As compared to @entity1 with recurrence (n=7), @entity1 with no recurrence (n=36) had significantly higher prevalence of clinical short @entity591 (61.1% vs. 14.3%, p=0.038), and EPS finding of DAVNP plus echo beats (80.6% vs. 42.9%, p=0.034). CONCLUSIONS: ESPA is a reasonable approach in @entity1 with documented @entity4710 , in particular in short @entity591 , who are not inducible at EPS. Larger studies are required to assess this practice.

title: Empiric slow pathway ablation in non-inducible XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity4710 :: ('MESH:D013617', 'Disease') :: ['supraventricular tachycardia', 'SVT']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['RP tachycardia']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

answer: @entity4710 :: (MESH:D013617,Disease) :: ['supraventricular tachycardia']